Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 24, 2024) - Military Metals Corp. (CSE: MILI) (OTC Pink: MILIF) (FSE: QN90) (the "Company" or "Military") announces it has signed a binding LOI to acquire further claims surrounding its West Gore Antimony Project ("West Gore" or the "Project") to consolidate the mineralized area. West Gore is a brownfield project with past production, historical high-grade drill results include 7.07 metres of 10.6 gpt gold and 3.4% antimony. During a period of production, it was Canada's most prominent antimony mine.West Gore consists of four Exploration Licenses comprising 585 hectares located in Hants County, Nova Scotia, Canada, and the newly acquired ground adds 388 hectares to the immediate northwest of the Project, comprising the balance of the West Gore antimony-gold mineralized system and its historical mine workings. The Company has a three-year option to acquire a 100% interest in the licenses for $235,000 spread over the term and the sellers will receive a 3% Net Smelter Royalty ("NSR") with standard buy-back provisions. It is anticipated the Company will announce the Definitive Agreement within ten days.The historical West Gore mines have a mining history dating back to 1883 and were a significant source of antimony during the First World War, most of which was shipped to England. Total production of gold and antimony between 1883 and 1917, the last recorded year of production, remains unknown. However, between 1914 and 1917 alone, nearly 32,000 metric tons were mined yielding over 7,000 metric tons of antimony concentrate grading 46% antimony. The total amount of gold recovered up to 1917 was estimated to be nearly 6,900 ounces. Aside from minor exploration work in the 1960s, the 1980s, and again over the past few years, the West Gore system remains essentially unexplored.With the acquisition of the new claims the Company has gained complete coverage over the entire mineralized system including all the historical mine workings and known antimony-gold occurrences with additional ground along trend in both directions as exhibited in Map 1 below. This in turn enables the Company to approach this antimony-gold system in its entirety to unlock future value. All relevant data are in the process of being compiled into an integrated digital database, with exploration plans to follow.Map 1: West Gore Project ClaimsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/227668_841965127489abc4_001full.jpgAntimony-gold mineralization at West Gore is hosted in graphitic and sulfide-bearing slates of the lower units of the Cambrian-age Halifax Formation that were deformed into a northeast-trending, upright, closed syncline and metamorphosed to greenschist facies during the regional Acadian orogeny. Mineralization occurs as stibnite, native antimony, aurostibnite, and antimony-gold alloys and oxides. Whereas the fold belt strikes northeast-southwest, mineralized structures trend northwest-southeast.The technical contents of this release were reviewed and approved by Avrom E. Howard, MSc, PGeo, geological consultant to Military Metals and a qualified person as defined by National Instrument 43-101.Investor Relations EngagementOn October 23, 2024, the Company engaged Clarkham Capital ("Clarkham") to provide investor relations services with a focus on the German stock market and the German-speaking investment community in support of the company listing on the Frankfurt Stock Exchange (the "Clarkham Agreement"). Pursuant to the terms of the Clarkham Agreement, Clarkham will, among other items, provide the Company with marketing services, which includes social media management, content creation, distribution, digital marketing, including, but not limited to, the preparation of articles and coverages on multiple financial platforms and newsletters, and translation and distribution of press releases in Germany and any other marketing services as agreed upon by the Company and Clarkham (the "Services"). The Clarkham Agreement has a term of two (2) months and is anticipated to commence on or about October 24, 2024. The Company will make a one-time payment to Clarkham of EUR 200,000 (CAD$298,340), as consideration for the Services. Sebastian Korbach will be providing the Services to the Company on behalf of Clarkham and may be contacted at +44-20-38839398 or cc@clarkham.com, or Flat 285, 61 Praed Street, London, UK W2 1ns. The Company will not issue any securities to Clarkham as compensation. Both Clarkham and Sebastian Korbach are arm's length to the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD OF DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.comFor enquiries, please call 604-722-5381 or 604-537-7556This news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-Looking information in this news release includes statements related to the completion of the acquisition of the Target by Military, as well as future plans for exploration activities, and assumptions related to the continuation of the global demand for antimony. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include entry into a definitive agreement in respect of the Acquisition, meeting the conditions to close the Acquisition, geopolitical developments related to the supply of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the properties that are the subjects of this news release, the results of any future exploration activities, which cannot be guaranteed, and such other factors as may impact both the Acquisition and any future activities in respect of the properties held by the Target. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-Looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227668 Copyright 2024 ACN Newswire via SeaPRwire.com.
TOKYO, October 25, 2025 - (ACN Newswire via SeaPRwire.com) - Kryterion Inc. announces the expansion of its Japan operations in an exciting move that will extend its software as a service (SaaS) certification and assessment software services for new and existing clients headquartered in Japan, reinforcing its commitment to client service excellence."Kryterion is set to be a premier provider of Japanese-language test delivery and locally staffed support services in Japan and for the international community," says William Dorman, Kryterion Chairman. "Simultaneously, we will introduce our highly secure, computer-based assessment management services to Japanese organizations serving the dynamic Japanese marketplace and the wider international community. Kryterion has a proven track record in transitioning from paper-based testing to computer-based testing and from onsite computer-based testing to secure, internet-based, proctored testing."Kryterion is a leading SaaS digital test development and test delivery provider in international markets, with approximately 1000 test center affiliates. It introduced secure, online proctored (OLP) exam delivery with a lockdown browser in 2007 and today provides global assessment services support, including Japanese language testing in Japan. Kryterion a subsidiary of the Drake International Group, which, through its subsidiaries, possesses a presence in 13 countries, including Japan, Korea, Taiwan, Hong Kong, Singapore, the Philippines, New Zealand, and Australia. Currently, Drake International's largest subsidiary in Japan is Drake Business Services Asia (DBSA). Led by CEO Grant Mackenzie, the company has been active in Japan since 2017. DBSA is a leading managed services provider, offering complete outsourced management of non-core support functions to deliver measurable cost reductions and efficiency improvements.According to Dorman, "The success of Drake Business Services Asia in Japan and across the region, coupled with growing acceptance of Kryterion's highly secure digital test development and test delivery services - especially in Japan's high technology sector - have prompted our decision to expand Kryterion's current presence in Japan dramatically."Contact Information:Yoshinori Nambo, Japan Sales Manager, Kryterion, Inc.Email: ynambo@KryterionOnline.com Website: www.Kryterion.com Buzz Walker, Chief Revenue Officer, Kryterion, Inc.Email: bwalker@KryterionOnline.com Website: www.Kryterion.com Copyright 2024 ACN Newswire via SeaPRwire.com.
TOKYO, Oct 25, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Marine Machinery and Equipment Co., Ltd (MHI-MME), a part of Mitsubishi Heavy Industries (MHI) Group, has concluded a licensing agreement with Jiangsu Masada Heavy Industries Co, Ltd. (Jiangsu Masada), a privately owned marine machinery manufacturer in China, for the manufacture and sale of MET Turbochargers, its exhaust gas turbine type turbochargers for two-stroke marine engines.Signing CeremonyWith the conclusion of this agreement, Jiangsu Masada plans to start manufacturing MET Turbochargers in 2025, focusing principally on assembly, and gradually expanding to full-scale production including processes other than assembly. MHI-MME's aim with this licensing agreement is to further penetrate the Chinese market with high-quality products and services.Jiangsu Masada has a long relationship with MHI Group, and has previously concluded licensing agreements for deck cranes in 2008, and steering gears and deck machinery in 2012. At present, Jiangsu Masada is a leading manufacturer of marine machinery, boasting the largest share in the Chinese market for deck cranes, deck machinery, and steering gears.MHI-MME developed the world's first non-water cooled turbocharger, the forerunner of the MET series, in 1965. High-efficiency, high-capacity models have since been added to the lineup, and today MET Turbochargers are one of the global standards for exhaust gas turbine types. Total cumulative production volume of MET Turbochargers has now reached 45,000 units, accounting for more than 40%(Note) of the global market (in fiscal 2023) for units used in marine two-stroke engines.Going forward, MHI-MME will continue to maintain and develop a positive cooperative relationship with Jiangsu Masada, and further proactively develop and market MHI brand marine machinery.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.
With a structured, step-by-step approach, EduEdge equips students not just for exams, but for lifelong mastery of English, giving parents a proven solution for their children's learning challenges
Singapore - October 25, 2024 - (SeaPRwire) - EduEdge is proud to announce its Formula-Style method, designed to transform the way struggling students master English. Despite English being Singapore's first language, many students struggle with deeper aspects of the language, such as comprehension, written expression and critical thinking. This proficiency gap affects not only their English grades but also their performance in other subjects. Research highlights a strong link between English language proficiency and academic achievement in areas like Maths and Science, underscoring the importance of mastering English for well-rounded academic success.
Traditional teaching methods often fall short of helping students achieve true language mastery. As English is the most widely spoken language globally, this lack of holistic proficiency concerns parents who want their children to excel, not just in exams but in life. EduEdge addresses this challenge through a revolutionary approach to English education.
Pioneered by founder Edwin Edangelus Cheng, EduEdge developed the groundbreaking Formula-Style method, designed to take the guesswork out of English learning. Backed by years of educational research, this structured approach goes beyond exam preparation by equipping students with the critical language skills and deep understanding necessary for lifelong success. By breaking down complex language concepts into easy-to-apply formulas, EduEdge empowers students to excel academically while mastering the communication skills essential for future professional achievements.
Edwin Edangelus Cheng's personal journey resonates with many parents and students. "I once was like your child," Edwin shares, recalling his struggles with English as a student from a Chinese-speaking family. His experience and years as a public school teacher, where he taught both English and Physics, inspired him to find structured methods for language learning.
"I saw how students approached learning English," Edwin explains. "They often rely on intuition without the structure or proper articulation needed for true mastery. In Physics, we see results quickly because of its formula and steps. I wondered, could the same formula-style approach work for English?" This question led to the development of EduEdge's Formula-Style method, offering a more structured and methodical way to teach and learn English.
What makes the Formula-Style method different is its ability to break down English learning into easy-to-apply and easy-to-remember formulas, similar to Maths and Science. This system, known as the Total English Mastery System (TEMS), helps students learn English in a faster, smarter and more effective way. Over the past 10 years, TEMS has helped more than 3,500 students from over 150 schools across Singapore improve by at least two grades, with many achieving high Bs and As in English and General Paper (GP) exams. Students who started with borderline or failing grades found success by mastering six core language skills—Vocabulary, Grammar, Reading, Writing, Listening and Speaking.
The impact of the Formula-Style method is shown in the stories of students who have experienced notable success. One such example is Angela Ray Oh, who, like many others, struggled with English during secondary school and was stuck at a C6 grade despite her determination. Her breakthrough came in Sec 4 when her mum enrolled her in EduEdge. After learning structured techniques, Angela's approach to English transformed, leading her to score an A2 for her O-Levels.
The benefits of these techniques extended beyond secondary school. While studying at Nanyang Technological University (NTU), Angela was awarded the Lee Kuan Yew (LKY) STEP Award, a highly competitive scholarship. The application process required writing two essays within 48 hours. Drawing on the writing techniques and critical thinking skills she gained at EduEdge, Angela crafted her submissions with confidence and aced both essays and the interview, demonstrating how EduEdge's method equips students for real-world success.
This success is no coincidence. EduEdge's Formula-Style method is powerful, but its true impact is realised through the exceptional educators who bring it to life. The highly qualified and passionate teachers at EduEdge are rigorously selected, ensuring that the method is delivered to its full potential. This combination of structured techniques and top-tier teaching creates a transformative learning experience that drives students' success.
Every journey at EduEdge begins with a Diagnostic Consultation Assessment (DCA) involving both parents and students. This personalised session provides a clear and quantifiable understanding of the child's current abilities and identifies specific areas that need improvement. Many parents believe misconceptions like, "My child speaks English, but their test results aren't great," or "My child reads a lot, but the results aren't improving." The DCA dispels these misconceptions by pinpointing underlying issues in comprehension, writing or critical thinking. This tailored approach allows EduEdge to develop a plan for effective improvement, ensuring more conducive learning.
Parental involvement is a key aspect of the EduEdge approach. Regular feedback is provided via email, based on detailed marking of the child's submitted work. This ensures parents stay up to date on their child's progress. Post-lesson consultations are also available to address any specific concerns.
Committed to continuous innovation, EduEdge keeps refining its methods to ensure students receive quality education not just for exams but for lifelong success. As part of its forward-thinking approach, EduEdge is exploring the use of AI and cutting-edge technology to personalise learning for every student further and extend educational support beyond the classroom. These tools will help create a more adaptive learning environment that tracks progress, identifies areas for improvement in real time and provides tailored resources.
Additionally, EduEdge is expanding its reach with care, ensuring that high teaching quality is never diluted while maintaining accessibility for students and parents. With existing branches in Serangoon and Bukit Timah, EduEdge is set to open a new branch in Marine Parade, further increasing accessibility across Singapore while upholding the high standards that has made it one of the country's leading English tuition specialists.
Experience the EduEdge difference today. Book a complimentary 60-minute DCA using the coupon code ELSUCCESS. Give your child, aged 10 to 18 (or Primary 4 to Junior College 2), the personalised support they need to improve their English skills and excel academically.
Media Contact
Edwin Edangelus Cheng
EduEdge English & GP Specialists
Website: https://eduedge.com.sg/DCA/
WhatsApp: https://wa.link/q77cvq
The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith.
Sectors: Top Story, Corporate News
SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
KUALA LUMPUR, MALAYSIA, Oct 24, 2024 - (ACN Newswire via SeaPRwire.com) - JBL®, the renowned lifestyle audio brand under Harman International, celebrated the launch of the “JBL Rewind Revolution Roadshow” today, bringing the party to life with its portable JBL PartyBox speakers and JBL PartyLight. Using AuracastTM technology, JBL PartyBox and JBL PartyLight sync seamlessly with each other and the music, creating a next-level sensory experience.JBL PartyLight BeamJBL PartyLight StickFor a more personal experience, the flagship True Wireless Stereo (TWS) earbuds, JBL Tour Pro 3, which is the first TWS with Auracast by JBL, rocketed onto the roadshow, with a Smart Charging Case with feature rich touchscreen, Real-Time True Adaptive Noise Cancelling and new audio transmitter for in-flight. The JBL Rewind Revolution Roadshow runs from 21-27 October at Mid Valley Mega Mall, East Entrance Atrium.The latest products designed to elevate your get-together or events are the JBL PartyLight Beam and JBL PartyLight Stick. While both add dynamic lighting synced to the best of the music, the JBL PartyLight Beam is a compact unit ideal for kinetic lighting effect. The JBL PartyLight Stick stands around one meter tall, is great for adding 330º room-filling mood enhancing features to your playlist. Both products use AuracastTM technology to connect effortlessly to a JBL PartyBox with a simple push of a button on each device. Control the speed, colours and patterns from the JBL PartyBox app. The built-in microphone with music detection algorithm, allows JBL PartyLight Beam and JBL PartyLight Stick to sync to the music playing in the room.The roadshow also featured JBL Partybox Club 120 and JBL PartyBox Stage 320, showcasing impressive JBL Pro Sound, sub-grille lights, and battery-powered performance. Whether it is dance or R&B, JBL PartyBox speakers deliver JBL’s renowned high-quality sound. These portable speakers come with a plethora of controls and features from the product-topping control panel, built-in handle, replaceable battery, IPX4 splashproof resistance, microphone and guitar inputs, plus Bluetooth to connect to your favourite music app from your preferred device.Mr. Henry Yap, Managing Director of Global Best United (M) Sdn Bhd said, “You can now party outside the box and enter a whole new soundscape with JBL PartyLight Beam and JBL PartyLight Stick as your essential elements for creating unforgettable parties. Whether it’s a holiday party or an intimate evening, synchronised music and lights can set the perfect mood.”“While JBL PartyBox Club 120 and JBL PartyBox Stage 320 can be paired with JBL PartyLight Stick and JBL PartyLight Beam, it is also very versatile and sturdy for use outdoor and indoor. Both comes with powerful JBL Pro Sound, futuristic lightshow, and splash proof, you can use it as a speaker or add a microphone, you can take your karaoke parties and outdoor celebrations to the next level”, Henry added.Mr. Mitchell Wong, Business Development Manager for JBL Malaysia said, “The technological advancements of the JBL Tour Pro 3 offer a feature-rich, fully customisable system. The JBL Tour Pro 3 is the flagship TWS earbud from JBL, with the latest audio technology like JBL Spatial 360 with Head Tracking, True Adaptive Noise Cancellation 2.0 and the first dual driver earbud.”The dual-driver design in the JBL Tour Pro 3 enhances audio performance, reducing distortion and improving sound clarity. The True Adaptive Noise Cancellation 2.0 system monitors and recalibrates over 50,000 times per second, recalibrating to adapt to environmental changes and compensating for sound leakage. The earbuds also ship with five additional ear-tips options - four silicon and one foam - for enhanced comfort and fit. Available in two colours, black and latte, the JBL Tour Pro 3’s smart case screen can be personalised with a photo, wallpaper and supports 13 languages.Availability. All featured JBL® products are available for purchase at Lazada, Shopee, and all leading retailers:ALL IT, Viewnet, Urban Republic, Thundermatch, Vivid Concepts, PC Image, SY Electric, THT, One Living, Harvey Norman, AES, Central Electronics, SS Audio, Brightstar Computers, Style Laser and EKS.Find out more about the JBL Products at https://www.jblonlinestore.com.my.Hi-Res Images. Please download hi-res product and lifestyle images from this link.For media information, kindly contact:Triven Marketing Group, for JBL® MalaysiaJazzmin WanEmail: j.wan@swanconsultancy.biz Copyright 2024 ACN Newswire via SeaPRwire.com.
Washington, D.C., Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Online scams wreak havoc across the Americas and globally, causing significant financial and emotional damage. The Global Anti-Scam Summit (GASS) Americas 2024, organized by the Global Anti-Scam Alliance (GASA) and hosted by Amazon.com, Inc., aims to combat these growing threats. The summit will feature over 30 hours of presentations, workshops, and interactive sessions across ten critical tracks, all focused on developing a global defense strategy to protect consumers and inform regulation.The summit will empower experts to take decisive action by focusing on the impact on victims, highlighting global scam statistics, explaining emerging scam tactics, and fostering international cooperation. The aim is to provide a roadmap for regulatory bodies to drive meaningful change.With $1.026 billion in global scam losses in 2023, this event seeks to mitigate further damage in 2024 and beyond.Day 1 will address the human and policy aspects of scams:Victim Impact: Led by AARP, this session delves into the emotional and financial toll on victims and their communities.Policy: The Aspen Institute will explore regulatory gaps and legislative solutions, sharing best practices from around the world.Law Enforcement: Chaired by UNODC, this session focuses on the collaboration between local and international agencies to disrupt scam networks.Data & Signal Sharing: GASA and DNS Research Federation will unveil plans for an international cybercrime exchange to reduce cybercrime by 50% in 10 years.Bank Collaboration: This session, led by Feedzai, will explore the critical role of banks in preventing scams.Day 2 will shift to specific industries and technologies most at risk:Financial Services: Featuring industry leaders like Capital One and Mastercard, this session will explore how multi-sector collaboration can build the perfect anti-fraud infrastructure.Telecom: Focuses on how telecom companies can improve security to protect consumers.Customer Digital Experience: Major platforms like Amazon will discuss how to strengthen protections at key digital touchpoints.Blockchain: Investigating scams in crypto and blockchain, chaired by Cube3.AI.Cybersecurity: Trend Micro will lead panels on advanced investigation techniques, focusing on scams like sextortion and pig butchering.Uniting Expertise for a Scam-Free Future"Consumers globally are facing a crisis with scams. Governments, private industry, and law enforcement must come together and act now," says Jorij Abraham, Managing Director of GASA. "Our aim at this summit is not only to discuss the problems but to build solutions that protect consumers worldwide."Confirmed Speakers:Glen Prichard, UNODCJean-Jacques Sahel, GoogleMatthew Noyes, U.S. Secret ServiceLaura Quevedo, MastercardBen Chance, ZelleAmy Nofziger, AARPMauro Ellovitch, MPMGThe summit will also launch the annual Global State of Scams Report 2024, offering an in-depth analysis of major scam trends and their impact.Join us in Washington, D.C., for this landmark event. Visit gasa.org/gass-2024-americas to view the full schedule and register.Contact InformationSam RogersMarketing Director, Global Anti-Scam Alliancesam.rogers@gasa.orgSOURCE: Global Anti-Scam Alliance (GASA) Copyright 2024 ACN Newswire via SeaPRwire.com.
SINGAPORE, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Vyasa Yoga SG, Singapore’s leading yoga institute, proudly celebrated its Silver Jubilee this month, marking 25 years of transforming lives through yoga and holistic health practices. Founded with S-VYASA, Vyasa Yoga SG has empowered thousands through its scientific, research-based yoga training and therapy programs, building a community of 3,000 certified yoga instructors and 500 yogi health therapists.The Silver Jubilee celebrations were inaugurated by esteemed guests, including Deputy High Commissioner of India Pooja Tillu, Neil Parekh, Chairman of Singapore Indian Chamber of Commerce and Industry (SICCI), Dr. H R Nagendra Guruji, Padma Shri awardee and renowned yoga guru, and Dr. Manjunath NK, Vice-President of the Asian Yoga Therapy Association, alongside Vyasa Yoga SG Founder, Manoj Thakur.To commemorate the milestone, Vyasa Yoga SG hosted the **International Conference on "Comprehensive Wellness Strategy" from October 19th to 20th, 2024 at the Galaxy Ballroom, CSC Tessensohn Club. The conference brought together 50 experts from 11 countries to explore integrating ancient yoga wisdom with modern science to enhance well-being. In her keynote address, Deputy High Commissioner Pooja Tillu emphasized the global relevance of yoga, stating: “Continue embracing yoga practice as a guiding light that will bring us together as a global family.”Manoj Thakur, Founder of Vyasa Yoga SG, reflected on the institute’s journey, “It has been a remarkable 25-year journey. Our success reflects the spirit of well-being we have cultivated in Singapore and beyond. We look forward to guiding people towards healthier, happier lives for many more years to come.”The event featured live yoga demonstrations and a special recognition ceremony to honor the institute’s significant contributions to health and wellness in Singapore. Vyasa Yoga SG is planning a series of events throughout the year to celebrate its 25th anniversary.About Vyasa Yoga SGEstablished to promote a healthy lifestyle through a scientific approach to yoga, Vyasa Yoga SG offers a variety of accredited programs for all ages and levels. With a mission to foster a culture of well-being, the institute continues to be at the forefront of holistic health in Singapore. For more information, visit https://vyasasingapore.com/. For further media queries contact:Ganesh Somwanshiganesh@mettai.world Copyright 2024 ACN Newswire via SeaPRwire.com.
SHANGHAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Everest Medicines (HKEX 1952.HK, “Everest”, or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Macau Medicine and Equipment Connect" policy, VELSIPITY(R) has officially been approved for patients with moderately to severely active ulcerative colitis (UC) by the Guangdong Provincial Medical Products Administration and can first be used in the Foshan Fosun Chancheng Hospital and the First Affiliated Hospital of Sun Yat-sen University, two of the medical institutions designated by the "Hong Kong and Macau Medicine and Equipment Connect" policy in the Greater Bay Area. Subsequently, VELSIPITY(R) will be introduced in other qualified hospitals under the connect policy. VELSIPITY(R) is now the third commercialized product of Everest Medicines.VELSIPITY(R) is an innovative advanced therapy that was officially approved by the Pharmaceutical Administration Bureau of Macau in April 2024. It is an oral treatment taken once daily for the treatment of patients aged 16 and above with moderately to severely active UC. UC is a chronic, relapsing, non-specific inflammatory disease, and as the disease progresses, the risk of disability and colorectal cancer incidence continues to rise. By 2030, the number of patients with UC in China is expected to more than double compared to 2019, reaching approximately 1 million, with a significant unmet need for innovative therapies.“The launch of VELSIPITY(R) in the Greater Bay Area accelerates the access to this advanced therapy in mainland China, offering a new option for patients with moderately to severely active UC." Said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “Everest Medicines is committed to expeditiously delivering innovative therapies to patients. Moving forward, we will keep leveraging our strengths and exploring innovative ways to improve the accessibility of these therapies. We plan to have VELSIPITY(R) submitted for new drug application in mainland China by the end of this year, further enhancing its accessibility and benefiting more patients." VELSIPITY(R) was developed by Arena Pharmaceuticals, which was acquired by Pfizer in 2022. Everest Medicines obtained exclusive rights to develop, produce, and commercialize VELSIPITY(R) in Greater China and South Korea from Arena as early as 2017. As a core product in the field of autoimmune diseases for Everest Medicines, VELSIPITY(R) was successively approved in Macau and Singapore in the first half of this year and was approved in the United States and the European Union in October last year and February this year, respectively. In addition, Everest Medicines recently submitted an new drug application for VELSIPITY(R) in Hong Kong, China.VELSIPITY(R) is the first and only advanced oral UC therapy approved for use in patients 16 years of age or older in the EU, and the ELEVATE UC 52 and ELEVATE UC 12 were the only studies of advanced therapies for UC to include patients with isolated proctitis. In the results of the Asian multi-center Phase 3 clinical trial of VELSIPITY(R) for the treatment of moderately to severely active UC announced in July this year, VELSIPITY(R) achieved positive topline data results in both the induction and maintenance treatment periods, with good safety profile, and is convenient to take once a day, providing further solid scientific basis and support for the wide application of the drug in clinical practice.About VELSIPITY(R) (etrasimod)VELSIPITY(R) is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds with S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Australia, Singapore, UK, Switzerland, Israel and Macau for VELSIPITY(R) in ulcerative colitis.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal diseases, infectious diseases and autoimmune disorders. For more information, please visit its website at www.everestmedicines.com.Forward-Looking Statements:This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2024 ACN Newswire via SeaPRwire.com.
Kawasaki and Nagoya, Japan, Oct 25, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Toyota Systems Corporation (Toyota Systems) today announced the successful completion of field trials leveraging Fujitsu’s generative AI offerings on Fujitsu Kozuchi (1) to improve productivity and accelerate the modernization of Toyota Systems’ system development and operations. The trials confirmed a 50% reduction in the work time required for system updates as compared to conventional manual processes. The reductions were achieved by automating incompatibility checks and removals and program correction associated with OS and programming language updates.Based on these positive results, Toyota Systems will commence practical application of this technology starting January, 2025.Toyota Systems develops and operates core systems for production, logistics, sales, and other functions used by the Toyota Group. Sometimes it is necessary to update the underlying OS and programming languages of these systems, but carrying out the associated tasks of compatibility checks, identifying affected areas, correcting programs, and conducting testing are labor-intensive.To address this challenge, Fujitsu and Toyota Systems started trials in October 2023, leveraging Toyota Systems’ expertise in core systems and Fujitsu’s software development and generative AI knowledge to find a way to streamline the updating process.The field trials focused on approximately 15,000 files developed in Java and SQLJ. The generative AI successfully extracted system-impacting incompatibilities based on provided information and automatically corrected the programs. Fujitsu and Toyota Systems confirmed the corrections were accurate and as a result achieved a 50% reduction in work time compared to if the tasks had been carried out manually.Moving forward, the two companies aim to further improve productivity by expanding the application of generative AI to other programming languages beyond Java and SQLJ, as well as to the testing phase. They also plan to deploy this technology to other Toyota Group systems and projects to accelerate modernization across the organization.Toyota Systems will leverage generative AI to radically improve system development efficiency, freeing up resources to drive further innovation and ultimately deliver new value to the mobility sector and society. Fujitsu will continue to support Toyota Systems’ initiatives and aims to commercialize an AI service that streamlines program updates, contributing to the Toyota Group's digital transformation (DX).Figure: Diagram of the update process using Fujitsu’s generative AI offerings on Fujitsu Kozuchi [1] Fujitsu’s generative AI offerings on Fujitsu Kozuchi: Interactive generative AI service for enterprises provided via Fujitsu Kozuchi through the Fujitsu Data Intelligence PaaS operations platformAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.About Toyota Systems CorporationToyota Systems is an IT solutions company established in Jan. 2019 by merging 3 different Toyota IT subsidiaries. The mission of the company is to support Toyota Motor Corporation and its group companies by developing innovative IT solutions and, by doing so, to contribute to develop the mobility society of the future. The number of the employees is approximately 3,000 and its support covers most of the Toyota’s main business areas such as R&D, production, logistics, sales, administration etc... For more information, please see https://www.toyotasystems.com/en/.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiriesToyota Systems CorporationPR and Management GroupInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.
HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - The 17th “C.C. Tan Life Science Award” ceremony was held at Shenyang Pharmaceutical University on October 9th. Dr. Chen Li, Founder and Chief Executive Officer of Hua Medicine, was awarded the “C.C. Tan Life Science Industrialization Award”. C.C. Tan Life Science Award has the highest honor as “the Chinese Nobel” in life science. In the context of the comprehensive construction of Chinese-style modernization and the development of new productivity, this award is a high recognition of Dr. Chen Li's outstanding contributions to the industrialization of life science achievements, and a full affirmation of his decades-long efforts to promote conceptual, technological and institutional innovations in biopharmaceutical industry.Dr. Chen Li participated in the award ceremony and received the “C.C. TanLife Science Industrialization Award”.“C.C. Tan Life Science Award” was proposed by Mr. Tan Jiazhen, one of the founders of modern genetics in China and an outstanding scientist and educator in modern China, which was approved by the Ministry of Science and Technology of the People's Republic of China, aims to promote the industrialization of China's life sciences research results and stimulate life scientists to make innovations. Since its establishment in 2008, C.C. Tan Life Science Award has been awarded annually to scientists, professors and young scholars who have made achievements in life science in the People's Republic of China and have made outstanding contributions to the industrialization of scientific and technological achievements in life science.With more than 30 years of experience in new drug R&D and management, Dr. Chen Li returned to Shanghai from the U.S. in 2004, and participated in the establishment of Roche R&D Center, the first R&D center of a multinational company in Shanghai, bringing the advanced experience, talent concept, technical standards and quality management system of international new drug R&D to China, and contributing to the establishment of the environment of China's biopharmaceutical industry. Dr. Chen Li has contributed to the establishment of China's biopharmaceutical industry environment.In 2010, Dr. Chen Li founded Hua Medicine in Zhangjiang, Shanghai, with the original intention of “China leads the way in pharmaceutical innovation”, adhering to the tenet of “patients first, innovation first, and good medicines for the people”, focusing on the unmet clinical needs, and concentrating on the research and development of first-of-its-kind new medicines for diabetes. Dr. Chen Li is not only one of the earliest pioneers to leave his executive position at a multinational pharmaceutical company to start a local innovative drug company, but also a leader in developing First-in-Class drugs in China.In September 2022, under the leadership of Dr. Chen Li, Hua Medicine's world's first, China's first, Class I National New Drug, Dorzagliatin (trade name: HuaTangNing®), which took ten years to develop independently, received marketing approval from the State Food and Drug Administration (SFDA), making it the first Glucose Kinesin Activator (GKA) approved and marketed globally, and the tenth class of diabetes therapeutic drugs.As the world's first GKA drug, Dorzagliatin utilizes the new concept of “repairing sensing, reshaping homeostasis, and treating diabetes at the source” to achieve the improvement of blood glucose homeostasis dysregulation in patients with type 2 diabetes mellitus, and to bring a brand-new treatment for diabetes mellitus patients, which is a major breakthrough in the history of drug research and development of China in the field of major chronic diseases. During the development of Hua Medicine, Dr. Chen Li has actively contributed to the development of China's biopharmaceutical industry. He has provided constructive opinions and suggestions for the system of marketing license holders and the system of patent linkage and patent protection, etc. He has cooperated with enterprises in the industry chain in the R&D and production of dorzagliatin to establish a joint innovation model, which has led to the development of the ecological development of the biopharmaceutical industry. In early 2024, Dr. Chen Li was awarded the first “Shanghai Outstanding Talent”. He is also the inventor of 119 granted invention patents and 270 invention patent applications and has been published more than 70 scientific papers in Nature Medicine, Lancet Diabetes Endocrinology, Nature Communication, PNAS, Diabetes, Obesity Metabolism, and the Journal of Biomedicine. PNAS, Diabetes, Obesity Metabolism, JACS, JOC and other international academic journals.About Hua MedicineHua Medicine is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin on hydrochloride-tolerated T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with varying degrees of renal function impairment (including end-stage renal impairment without dialysis). Hua Medicine partnered with Bayer, a leading global pharmaceutical company, to commercialize HuaTangNing in China, benefiting diabetic patients and their families.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsE-mail: ir@huamedicine.comMediaE-mail: pr@huamedicine.com Copyright 2024 ACN Newswire via SeaPRwire.com.
DUBAI, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - Dubai International Financial Centre (DIFC), the leading global financial hub in the Middle East, Africa and South Asia (MEASA) region, announces the 2nd edition of the Future Sustainability Forum. Scheduled for 4 and 5 December 2024 at the Madinat Jumeirah, Dubai, the Forum will focus on mobilising sustainable practices, engaging in influential discussions on sustainable development, working towards environmental conservation, social equity and innovation.The announcement of the 2nd edition of the Forum underscores DIFC’s commitment to advancing UAE sustainability priorities alongside initiatives such as the DIFC Sustainable Finance Catalyst which aims to grow sustainable finance flows from Dubai to USD 100+ billion by 2030.The Forum coincides with the first anniversary of COP28 being hosted in the UAE and is set to attract over 3,000 participants. The event will mobilise industry leaders, investors, tech disruptors, and policymakers into achieving the United Nations Sustainable Development Goals (SDGs) and contributing to the delivery of the Paris Agreement, whilst aiming to channel investment flows between the global north and south to accelerate climate action.Alya Al Zarouni, Chief Operating Officer of DIFC Authority and Co-Chair of the Dubai Sustainable Finance Working Group, said, “The DIFC organised Future Sustainability Forum is a vital platform for collaborative action towards a more sustainable future. As the global economic landscape evolves, so must our commitment to responsible and inclusive growth. At DIFC, we are proud to be convening this gathering of industry leaders, innovators, and policymakers to address the most pressing environmental and social challenges of our time. Together, we can forge new pathways to a more resilient and sustainable future for financial services and other important industries.”Dr Bernd van Linder, Chief Executive Officer of the Commercial Bank of Dubai, the presenting sponsor of the Forum, stated, "Commercial Bank of Dubai is proud to support the UAE's sustainability ambitions through our participation in the Future Sustainability Forum 2024 as Presenting Sponsor. Our proactive approach in addressing environmental challenges, exemplified by the successful issuance of CBD's inaugural green bond, demonstrates our alignment with global environmental goals."The Forum will address critical sustainability issues across eight core pillars spanning different industries including banking and finance, construction, renewable and future energy, transportation and mobility, manufacturing and production, recycling and waste management, sustainable technology, and agriculture and food production.In addition to the packed conference agenda that will feature over 100 sustainability and climate action expert speakers, the Forum will bring together the most innovative solutions and service providers from across the global sustainability landscape through the Climate Action & Renewable Energy Expo (CARE).Government entities in the UAE have spearheaded a range of comprehensive sustainability programmes in the pursuit of a net-zero future. Initiatives such as the Dubai Clean Energy Strategy 2050, the UAE Net Zero 2050 strategic initiative, and the UAE Vision 2070, emphasise on a commitment to renewable energy adoption, water conservation, waste management, and sustainable urban development.For more information and to register, please visit the Future Sustainability Forum website.About Dubai International Financial CentreDubai International Financial Centre (DIFC) is one of the world’s most advanced financial centres, and the leading financial hub for the Middle East, Africa, and South Asia (MEASA), which comprises 77 countries with an approximate population of 3.7bn and an estimated GDP of USD 10.5trn.With a 20-year track record of facilitating trade and investment flows across the MEASA region, the Centre connects these fast-growing markets with the economies of Asia, Europe, and the Americas through Dubai. DIFC is home to an internationally recognised, independent regulator and a proven judicial system with an English common law framework, as well as the region’s largest financial ecosystem of 43,800 professionals working across over 6,150 active registered companies – making up the largest and most diverse pool of industry talent in the region. The Centre’s vision is to drive the future of finance through cutting-edge technology, innovation, and partnerships. Today, it is the global future of finance and innovation hub offering one of the region’s most comprehensive FinTech and venture capital environments, including cost-effective licensing solutions, fit-for-purpose regulation, innovative accelerator programmes, and funding for growth-stage start-ups. Comprising a variety of world-renowned retail and dining venues, a dynamic art and culture scene, residential apartments, hotels, and public spaces, DIFC continues to be one of Dubai’s most sought-after business and lifestyle destinations. For further information, please visit our website: difc.ae, or follow us on LinkedIn and X @DIFC.For media enquiries, please contact:Nivine William | Nisha CelinaBurson | bursonglobal.comnivine.william@bursonglobal.com | nisha.celina@bursonglobal.com Rasha Mezher | Dubai International Financial Centre Authority Manager, Marketing & Corporate CommunicationsRasha.Mezher@difc.ae Hussain AlZaabi | Dubai International Financial Centre AuthorityManager, DIFC Innovation Hubhussain.alzaabi@difc.ae Shadi DawiDirector - PR & Media+971 55 498 4989shadi@tresconglobal.com Copyright 2024 ACN Newswire via SeaPRwire.com.
HONG KONG, Oct 25, 2024 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place from November 15-19, 2024 in San Diego, California. The presentations include post-hoc analyses of the Phase 2a clinical study of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with metabolic dysfunction-associated steatohepatitis (MASH) and comorbid type 2 diabetes mellitus (T2DM) (NCT03656744).“These data provide additional characterization of the efficacy and safety of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with MASH and T2DM. If further studies confirm these findings, HTD1801 could potentially offer a more effective solution for patients who do not respond adequately to GLP-1 receptor agonists. In addition, the observations of improved GI tolerance over time suggests that HTD1801 may be an attractive option for long-term management of chronic conditions such as MASH and T2DM. The ongoing Phase 2b study (CENTRICITY, NCT05623189), fully enrolled in 1Q 2024, evaluates the histological benefit of HTD1801 in patients with MASH and T2DM. We look forward to announcing the CENTRICITY results which we expect in the first half of 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.“Efficacy of Berberine Ursodeoxycholate (HTD1801) Compared to Ongoing Use of GLP-1 Receptor Agonists in Patients with MASH and T2DM” (Abstract 3218, Poster Presented November 17th)About the Abstract: As GLP-1 Receptor Agonists (GLP-1RAs) are prominently used in patients with T2DM and gaining attention as a potential treatment for MASH, this post-hoc comparative efficacy analysis evaluated ongoing GLP-1RA use compared to newly initiated HTD1801 treatment. This analysis suggests that HTD1801 provides greater improvements in markers of liver injury and inflammation, glycemic control, weight loss, and lipid metabolism compared to ongoing GLP-1RA use. These findings are important as they suggest that HTD1801 could provide additional benefit to patients with MASH and T2DM, on concomitant GLP-1RA treatment.“Time Course of Onset, Incidence, and Prevalence of Gastrointestinal Adverse Events with HTD1801 (Berberine Ursodeoxycholate) in Patients with MASH and T2DM” (Abstract 3219, Poster Presented November 17th)About the Abstract: Across several indications, the most commonly occurring adverse events (AEs) in studies of HTD1801 have been mild to moderate gastrointestinal (GI) AEs, primarily diarrhea and nausea. The purpose of this post-hoc analysis was to characterize the time course and severity of GI AEs in patients with MASH and T2DM treated with HTD1801 for 18 weeks. Based on this analysis, the incidence of GI-related AEs peaks within the first 4 weeks of treatment, was mild to moderate in severity, and importantly, showed a decreasing incidence and prevalence over the course of treatment. These data demonstrate that HTD1801 is generally well-tolerated and with continued treatment, GI tolerance improves supporting its potential long-term use in chronic diseases, such as MASH.About HighTide TherapeuticsHighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both MASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.For more information, please visit www.hightidetx.com Copyright 2024 ACN Newswire via SeaPRwire.com.
香港, 2024年10月25日 - (亚太商讯 via SeaPRwire.com) - 针对公司近日股价持续上涨，引发媒体质疑涉嫌操纵股价的报导、侨雄国际(00381.HK)今日盘后发布公告称，经公司董事会作出一切合理查询后所知、所悉及所信，董事会坚决否认媒体报导中包含的猜测，并认为报导事项不准确且具有误导性。侨雄国际在公告中进一步指出，公司已经谘询其法律顾问，将会作出进一步行动。此外公司向负责传播误导性及恶意陈述，恶意沽空从而获益的有关实体及╱或相关个人及任何人，导致的损害或其他补偿，保留采取法律行动之权利。10月22日，有媒体发布题为《16个交易日翻了近30倍，侨雄国际（00381）全靠两个"经纪商"雄起？》，指出截至10月21日，中国北方证券和长桥证券两个经纪商近20个交易日分别净买入了0.92亿股和0.27亿股，持股比例分别为14.02%及3.42%，而其他经纪商仅有少量买入，由此质疑公司股价存在被操纵的嫌疑。侨雄国际执行董事兼联席主席李立中对媒体回应称，价格的波动是市场对公司未来预期的反应，是正常的市场行为。首先，乘著近期港股的升浪，很多公司股票都有明显的升幅。加上公司近来管理层的变动，委任了有丰富资历以及管理经验的董事，这些可被股东看作利好消息，公司股价上涨表示股东对公司前景乐观。二零二四年十月四日，侨雄国际委任李立中为执行董事兼联席主席。李立中长期从事人工智慧、元宇宙、智联网路、区块链科学研究，这些领域的研究成果不仅推动了科技进步，而且为人类的生活带来了巨大的改变。其工作成果向世界展示了中国科学家的智慧和实力，也为中国在科技领域的发展做出了重要贡献。侨雄国际表示，国家"十四五"规划中提出迎接数字时代，启动数据要素潜能，推进网络强国建设，加快建设数字经济、数字社会、数字政府，以数字化转型整体驱动生产方式、生活方式和治理方式变革。基于"十四五"规划所带来的数字化新浪潮，各行各业将获得更多发展机遇，面对中国社会经济发展新阶段、新特征，公司未来将专注于深化现有业务开发及运营，向数字媒体经销等方向稳定发展，丰富业务的多元化结构，使得公司更加稳步向前。侨雄国际在公告中表示，董事会经作出在相关情况下有关公司的合理查询后，董事会确认，其并不知悉导致价格或成交量波动的任何原因，或任何必须公布以避免公司证券出现虚假市场的资料。李立中强调，该报导仅凭市场交易券商名字片面的指责怀疑公司操纵市场，期间并未与上市公司做任何的沟通与确认，是典型恶意沽空的犯罪行为。公司会对其新闻前恶意做空行为和新闻后操纵市场行为发出律师函和诉讼，以维护广大投资者权益。前述媒体报导称，"侨雄国际基本面并不好，公司主要从事玩具及礼品制造及销售、天然资源勘探、水 果种植、休闲及文化及中草药多种业务，业务表现平淡，业绩收入已经连续两个半年度下行，且盈利能力持续下降。今年该公司业务模式并未有重大变化，唯一变化是在10月10日，拟将公司名称更名为权识国际集团（中文名称）。"侨雄国际近期发布公告，拟将公司名称更改为"AOM International Group Company Limited"，并采用"权识国际集团股份有限公司"作为其第二中文名称。据悉，集团的业务有六大可呈报分类，由于各业务均有不同的经济特征，因此各业务被分开管理。对此李立中表示，侨雄国际更名为权识国际。未来会通过相关专利技术对公司各板块业务做全方位的数位经济转型，通过生产资料的标识化，为公司的各个板块注入新的价值与活力。因此引发股价上涨和投资者购买属于正常市场现象。李立中指出，目前侨雄国际的资金状况非常健康，公司管理层对公司发展的前景保持绝对的乐观态度，会考虑在未来继续增持公司股票，以带给市场及公司股东信心，稳定因为不实报道，故意抹黑而影响的公司股价。关于后续的业务安排，公司会按照上市公司管理要求走合规的业务流程正常公告披露。公司谨提醒公司股东及潜在投资者，关注公司于联交所网站(http://www.hkexnews.hk/index.htm) 。 Copyright 2024 亚太商讯 via SeaPRwire.com.
